Search
Dextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]
Valaciclovir
go.drugbank.com/drugs/DB00577ApprovedInvestigationalIt was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline [L5671]. Valacyclovir is the L-valine ester of aciclovir. … It is caused by infection with the herpes simplex virus (HSV). Infection with this virus is lifelong with periodic episodes of reactivation [A175903].
Fenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnIt is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency. … clinical practice, central nervous system stimulative effects are less notorious than with some other agents such as diethylpropion and mazindol. [7] In the United States fenproporex was never approved by
Sodium phosphate, monobasic
go.drugbank.com/drugs/DB09449ApprovedInvestigationalSodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
Isosorbide dinitrate
go.drugbank.com/drugs/DB00883ApprovedInvestigationalIts actions are similar to nitroglycerin but with a slower onset of action.
Dapsone
go.drugbank.com/drugs/DB00250ApprovedInvestigationalA sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae.
Duloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigational[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.
Golotimod
go.drugbank.com/drugs/DB05475Investigationalclearance of mycobacteria, improved cavity healing, improvements in immune parameters and reduced symptoms (fever, weakness, sweating, dry cough, productive cough, dyspnea, chest pain, tachycardia) without
Benznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.